96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

作者：C. Zhou, S. Ren, Jiyan Chen, Xin-qian Xu, Ying-Bo Cheng, Gongyan Chen, Y. Pan, Yong Fang, Qun Wang, Yunchao Huang, W. Yao, R. Wang, X. Li, W. Zhang, Y. Zhang, S. Hu, R. Guo, Z. Yang, Wang Lifeng · 年份：2021 · DOI：10.1016/S1556-0864(21)01938-9 · 被引用次数：9 · 研究领域：Medicine